Molnunat (Molnupiravir): Patient Information Leaflet
Basic Product Information
| International Nonproprietary Name (INN) | Molnupiravir |
| Australia Brand Names | Molnunat, Lagevrio |
| Anatomical Therapeutic Chemical (ATC) Code | J05AXXX (pending permanent code assignment) |
| Available Forms and Strengths | Capsules, 200 mg |
| Manufacturers | NATCO Pharma, Merck Sharp & Dohme (MSD) |
| Prescription Status | Prescription only (Schedule 4 in Australia) |
Mechanism of Action
Simple Explanation: Molnupiravir is an antiviral medicine. When you take it, the medicine stops the virus that causes COVID-19 from growing in your body, making it harder for the virus to spread and cause illness.
Specialist Explanation: Molnupiravir is a prodrug of N-hydroxycytidine (NHC), which is incorporated by the viral RNA-dependent RNA polymerase. This leads to accumulated errors (“error catastrophe”) in the viral RNA, effectively inhibiting replication of SARS-CoV-2.
Pharmacokinetics
| Absorption | Peak plasma concentration typically within 1.5 hours of oral intake. |
| Metabolism | Rapidly converted in plasma to its active form (NHC), primarily metabolised by hydrolysis. |
| Elimination | Mainly excreted via urine as metabolites. |
| Duration of Action | Active drug remains detectable in plasma for up to 6–12 hours. |
Use in Everyday Life and Best Practices
- Typical Dose: For most adults, the recommended dose is 800 mg (four 200 mg capsules) taken twice daily for five days.
- How to Take: Swallow the capsules whole with water. Take at the same time every morning and evening to maintain an even amount in your body.
- Timing: Begin treatment within 5 days of COVID-19 symptom onset to ensure best results.
- Who Should Not Use: Not suitable for children under 18 years, pregnant or breastfeeding women unless specifically advised by a doctor, nor patients with severe allergies to molnupiravir or any inactive ingredients.
Dosing: Morning vs Evening
Molnupiravir should be taken twice daily, approximately 12 hours apart. Morning and evening dosing helps keep consistent drug levels in your system.
Morning Use: Helps set a routine with breakfast.
Evening Use: Take with dinner or before bed—avoid missing evening doses by linking with a regular activity.
Tip: Use alarms, a pill organiser, or a dosing chart.
Taking with Food or on an Empty Stomach
- Molnupiravir may be taken with or without food—taking with food can reduce possible stomach upset.
- Consistent timing (e.g., with breakfast and dinner) may fit well with typical Australian dietary habits.
- If you experience nausea, try taking capsules with a small meal or a glass of milk.
Interactions and Warnings
| Type | Common Interactions |
| Food | No significant interaction, but taking with food may improve tolerability. |
| Alcohol | No specific interaction, but best to avoid excessive alcohol during acute infection to support immune function. |
| Medications | Avoid concurrent use with drugs that share serious side effects (e.g., severe allergic reactions). No major drug–drug interactions have been documented; discuss all medication and supplement use with your healthcare provider. |
Indications
| Indication | Status in Australia |
| Treatment of mild-to-moderate COVID-19 in adults at risk of progression | Approved |
| Post-exposure prophylaxis of COVID-19 | Not Approved (off-label use under clinical trial) |
| Other viral respiratory illnesses | Not approved or recommended |
Dosing According to Clinical Indication
| Patient Group | Indication | Dose | Duration |
| Adults (>18 years) | Mild-to-moderate COVID-19 | 800 mg (4 capsules) twice daily | 5 days |
| Children (<18 years) | Any | Not recommended | N/A |
| Elderly | Mild-to-moderate COVID-19 | Same as adults (dose adjustment not required) | 5 days |
| Pregnant/Breastfeeding | Any | Not recommended unless benefit outweighs risk; specialist consultation required | N/A |
Safety Profile and Side Effects
- Common: Diarrhoea, nausea, dizziness, headache.
- Less Common: Skin rash, mild allergic reactions.
- Rare: Severe hypersensitivity, bronchospasm.
- Special Precautions: Potential mutagenicity in preclinical studies; not recommended for pregnant or breastfeeding women, and those wanting to conceive (male and female) during and for at least 4 days (women) or 3 months (men) after treatment unless advised otherwise.
| Side Effect | Frequency | What to Do |
| Diarrhoea | Common | Stay hydrated, contact GP if severe |
| Nausea | Common | Take with food, report if persistent |
| Headache | Common | Use simple analgesics if necessary |
| Rash/allergy | Uncommon | Stop medication and seek urgent medical advice |
Guidelines for Proper Use
- Start as soon as possible after diagnosis—preferably within 5 days of symptom onset.
- Do not miss doses. If you forget, take it as soon as you remember (unless it’s almost time for your next dose—never double dose).
- Use a calendar, alarm, or pharmacist-provided chart to track doses.
- Continue the full course even if you feel better—stopping early may reduce effectiveness.
- Keep capsules in their original container in a cool, dry place below 25°C—do not refrigerate or freeze.
- Do not share this medicine with others.
- Consult your GP or pharmacy if you develop new/unusual symptoms during the course.
- Australian pharmacists can advise on taking Molnunat together with regular medications or supplements.
Alternative Treatment Options
- Paxlovid (nirmatrelvir/ritonavir):
- Oral antiviral, reimbursed under PBS in Australia for eligible COVID-19 patients.
- Similar efficacy, but interacts with more common medications.
- Remdesivir:
- IV antiviral, hospital use only, usually for moderate–severe COVID-19 cases.
- Supportive care:
- Paracetamol, fluids, rest; oxygen therapy in severe cases (hospital-based).
- Comparative Overview:
- Molnunat: oral, minimal major interactions, not for severe renal/hepatic impairment, not for pregnancy.
- Paxlovid: oral, many drug–drug interactions, effective in similar patient groups.
Legal, Registration, and Reimbursement Status in Australia
- Registered by the Therapeutic Goods Administration (TGA) as a prescription-only medicine.
- Supplied under the Pharmaceutical Benefits Scheme (PBS) for eligible high-risk adults with confirmed COVID-19.
- Strict prescription requirements; only available from community and hospital pharmacies on doctor’s script.
- Not for over-the-counter or self-prescription use.
Latest Research and Clinical Guidance (2022–2025)
- The PANORAMIC study (UK, 2022–2023) found limited benefit in low-risk groups but benefit in high-risk/elderly outpatients (Lancet, 2022).
- Australian guidelines (Australian Technical Advisory Group on Immunisation, ATAGI, 2023–2024) recommend use in patients at high risk of severe COVID-19 outcomes within five days of symptom onset.
- 2024 UK NICE Update: No long-term safety signal observed; not recommended in pregnancy due to preclinical mutagenicity concerns (BMJ, 2023–2024).
Availability and Delivery
| Pack Size | Capsule Count | Indicative PBS Patient Price* |
| Standard | 40 (full 5-day course) | $42.50 (PBS-concessional), up to $140 (private prescription) |
*Actual price depends on concession status, prescription, and pharmacy pricing.
Pharmacies can usually supply within 24–48 hours via Metro, and 2–4 business days to most regional centres (Sydney, Melbourne, Brisbane, Perth, Adelaide, Canberra, Hobart, Darwin).
Frequently Asked Questions
- When should I start taking Molnunat?
Start as soon as possible, ideally within 5 days of COVID-19 symptoms starting. Early use is vital for effectiveness. - Can I take Molnunat with my regular medicines?
Molnunat has few known interactions, but always inform your GP and pharmacist of all current medications, including herbal or nutritional supplements. - Is Molnunat safe for pregnant or breastfeeding women?
No. Currently, it is not recommended in pregnancy or breastfeeding. Plan effective contraception during and for several days after use. - What should I do if I miss a dose?
Take it as soon as you notice, unless your next dose is soon. Never take two doses at once. - Do I need to isolate while taking Molnunat?
Yes, follow current NSW Health or national guidelines for isolation if you test positive for COVID-19, even when on treatment.
For more information, please consult your GP, pharmacist, or refer to the latest ATAGI and TGA guidance. Always follow your healthcare provider’s instructions when using Molnunat (molnupiravir).
